Cajal Neuroscience
Seattle, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $96M
Overview
Leveraging human brain maps and genetics to discover novel targets for Alzheimer's and Parkinson's disease.
NeuroscienceGenetics & Genomics
Technology Platform
An integrated platform that creates high-resolution molecular maps of the human brain to identify and validate novel therapeutic targets for neurodegenerative diseases based on human genetics and functional genomics.
Funding History
1Total raised:$96M
Venture$96M
Opportunities
Potential to redefine the therapeutic landscape for Alzheimer's and Parkinson's by discovering entirely new, genetically-validated disease mechanisms.
Risk Factors
Extremely long development timelines, high cost of clinical trials, and the persistent risk of clinical failure despite strong preclinical human data.
Competitive Landscape
Competes in the challenging neurodegeneration space with other data-driven discovery companies, requiring superior target validation to attract partnership interest.